

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Stürzebecher et al.	Confirmation No.:	4120
Serial No.:	10/540,958	Art Unit:	1628
371(c) Date:	January 3, 2006	Examiner:	M. Sznajdman
Customer No.:	21559		
Title:	ACYLATED 4-AMIDINO-AND 4-GUANIDINOBENZYLAMINES FOR INHIBITION OF PLASMA KALLIKREIN		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of the U.S. patent application publication.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after the mailing of a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. I, the undersigned, hereby certify that each item of information contained in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application, dated May 12, 2011, and received May 24, 2011, which is not more than three months prior to the filing of this statement.

The references submitted in this IDS were cited in the extended European Search Report (EESR) for the corresponding European Patent application EP 10013065.7-2123. A copy of the EESR, which is in the German language, is also provided.

Applicants note that DE 101 02 878 and WO 02/062829 are not written in the English language. English language abstracts are provided as an explanation of relevance of the documents, in accordance with M.P.E.P. § 609.04(a)(III).

The following documents cited in the EESR are not enclosed because these references, or a corresponding English language counterpart, were included in an IDS filed with the Office on April 8, 2010.

WO 00/58346;

WO 02/14349;

DE 100 29 014;

DE 100 29 015;

Künzel et al., *Bioorganic and Medicinal Chemistry Letters*, 12:645-648 (2002);

WO 03/076391 (U.S. Patent Publication No. 20050176993);

WO 03/076457 (U.S. Patent Publication No. 20050119190);

WO 03/053999 (U.S. Patent Publication No. 20040266766);

WO 03/070229;

DE 102 12 555; and

Zeslawska et al., *Journal of Molecular Biology*, 328(1):109-118 (2003).


The following reference is not enclosed because the publication of the U.S. counterpart application (U.S. Patent Publication No. 20040087511) was cited by the Office in an Office Action dated June 11, 2009:

WO 02/062829.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 24 June 2011



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045